Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In consultation
In consultation: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (5 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Consultation end date
Consultation end date
From date
To date
Apply date filters
Type
Type
Guidance (16)
Guidance programme
(
5 selected
)
Guidance programme
Antimicrobial prescribing guidelines (0)
Clinical guidelines (4)
Diagnostics guidance (0)
Early value assessment (4)
HealthTech guidance (10)
Highly specialised technologies guidance (0)
Interventional procedures guidance (3)
Late stage assessment (1)
NICE guidelines (4)
Technology appraisal guidance (12)
Apply filters
Showing 1 to 10 of 16
Sort by
Date
Title
Apply sorting
Guidance programme: Technology appraisal guidance
`Remove $Guidance programme: Technology appraisal guidance filter`
Guidance programme: Clinical guidelines
`Remove $Guidance programme: Clinical guidelines filter`
Guidance programme: Antimicrobial prescribing guidelines
`Remove $Guidance programme: Antimicrobial prescribing guidelines filter`
Guidance programme: Diagnostics guidance
`Remove $Guidance programme: Diagnostics guidance filter`
Guidance programme: Highly specialised technologies guidance
`Remove $Guidance programme: Highly specialised technologies guidance filter`
Guidance and quality standards in consultation
Title
Consultation
Type
Consultation end date
Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Draft guidance
NICE guideline
11 August 2026
Bladder cancer: diagnosis and management (update)
Scoping
NICE guideline
6 August 2026
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
5 August 2026
Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Draft guidance
Technology appraisal guidance
31 July 2026
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Final draft guidance
Technology appraisal guidance
23 July 2026
Secukinumab for treating relapsed polymyalgia rheumatica ID6599
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
22 July 2026
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]
Draft guidance
Technology appraisal guidance
21 July 2026
Headaches (update): Prophylactic treatment of migraine - Candesartan
Draft scope consultation
NICE guideline
21 July 2026
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]
Draft guidance
Technology appraisal guidance
17 July 2026
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing
Draft guidance consultation
NICE guideline
10 July 2026
Current page
1
2
Page
1
of
2
Next page
Results per page
10
25
50
All
Back to top